EGFR and lung adenocarcinoma: EGFR mutations occurred in half of our cases, in agreement with other populations, being higher than European and lower than Asian populations (Figure 2; Supplementary Table S5).1,2,4,6 Similar to our results, EGFR-TKi sensitizing exon 19 deletions are found in 50% of patients diagnosed with lung adenocarcinoma, while exon 20 insertions are less common globally.1,6,8TP53 was our second most mutated gene (39.5%).